The messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.
Germany-based messenger RNA (mRNA) drug developer CureVac closed a $640m financing round on Tuesday that included $171m from pharmaceutical firm GlaxoSmithKline, which signed a strategic partnership with it this week.
The round includes $343m in the form of the funding commitment made by German development bank KfW last month and $126m in additional funding from investors including sovereign wealth fund Qatar Investment Authority.
CureVac is developing therapeutics designed to leverage mRNA in order to induce different levels of…
